R. M. Parakh

Biogenomics Ltd. is a leading biopharmaceutical company based in Mumbai, IN that focuses on diabetes and cancer care. The company's unique products in the pipeline include Next-Gen diabetic medications (Long and fast-acting Insulin) and Cancer Immunotherapy. The Indian company provides advanced cGMP production, manufacturing, research, and development facilities, and are WHO GMP certified with advanced formulation capabilities. Biogenomics is fully equipped and DSIR approved with more than 200 total employees, including 70 scientists, with a vision of adaptive innovations. The company was founded by Sanjay Sonar and the CEO is R. M. Parakh.

Biogenomics Ltd. is a leading biopharmaceutical company based in Mumbai, IN that focuses on diabetes and cancer care. The company's unique products in the pipeline include Next-Gen diabetic medications (Long and fast-acting Insulin) and Cancer Immunotherapy. The Indian company provides advanced cGMP production, manufacturing, research, and development facilities, and are WHO GMP certified with advanced formulation capabilities. Biogenomics is fully equipped and DSIR approved with more than 200 total employees, including 70 scientists, with a vision of adaptive innovations. The company was founded by Sanjay Sonar and the CEO is R. M. Parakh.

Biogenomics Ltd. is a leading biopharmaceutical company based in Mumbai, IN that focuses on diabetes and cancer care. The company's unique products in the pipeline include Next-Gen diabetic medications (Long and fast-acting Insulin) and Cancer Immunotherapy. The Indian company provides advanced cGMP production, manufacturing, research, and development facilities, and are WHO GMP certified with advanced formulation capabilities. Biogenomics is fully equipped and DSIR approved with more than 200 total employees, including 70 scientists, with a vision of adaptive innovations. The company was founded by Sanjay Sonar and the CEO is R. M. Parakh.

Biogenomics Ltd. is a leading biopharmaceutical company based in Mumbai, IN that focuses on diabetes and cancer care. The company's unique products in the pipeline include Next-Gen diabetic medications (Long and fast-acting Insulin) and Cancer Immunotherapy. The Indian company provides advanced cGMP production, manufacturing, research, and development facilities, and are WHO GMP certified with advanced formulation capabilities. Biogenomics is fully equipped and DSIR approved with more than 200 total employees, including 70 scientists, with a vision of adaptive innovations. The company was founded by Sanjay Sonar and the CEO is R. M. Parakh.

Biogenomics Ltd. is a leading biopharmaceutical company based in Mumbai, IN that focuses on diabetes and cancer care. The company's unique products in the pipeline include Next-Gen diabetic medications (Long and fast-acting Insulin) and Cancer Immunotherapy. The Indian company provides advanced cGMP production, manufacturing, research, and development facilities, and are WHO GMP certified with advanced formulation capabilities. Biogenomics is fully equipped and DSIR approved with more than 200 total employees, including 70 scientists, with a vision of adaptive innovations. The company was founded by Sanjay Sonar and the CEO is R. M. Parakh.